- Home
- MCRB vs MRBK Comparison
MCRB vs MRBK Comparison
Compare MCRB & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MRBK
- Stock Information
- Founded
- MCRB 2010
- MRBK 2004
- Country
- MCRB United States
- MRBK United States
- Employees
- MCRB N/A
- MRBK N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MRBK Major Banks
- Sector
- MCRB Health Care
- MRBK Finance
- Exchange
- MCRB Nasdaq
- MRBK Nasdaq
- Market Cap
- MCRB 144.8M
- MRBK 162.3M
- IPO Year
- MCRB 2015
- MRBK 2017
- Fundamental
- Price
- MCRB $16.87
- MRBK $14.73
- Analyst Decision
- MCRB Hold
- MRBK Buy
- Analyst Count
- MCRB 3
- MRBK 2
- Target Price
- MCRB $14.33
- MRBK $17.50
- AVG Volume (30 Days)
- MCRB 88.5K
- MRBK 53.5K
- Earning Date
- MCRB 11-05-2025
- MRBK 10-23-2025
- Dividend Yield
- MCRB N/A
- MRBK 3.42%
- EPS Growth
- MCRB N/A
- MRBK 75.95
- EPS
- MCRB 0.62
- MRBK 1.77
- Revenue
- MCRB $351,000.00
- MRBK $109,758,000.00
- Revenue This Year
- MCRB N/A
- MRBK $26.84
- Revenue Next Year
- MCRB N/A
- MRBK $8.90
- P/E Ratio
- MCRB $26.91
- MRBK $8.27
- Revenue Growth
- MCRB N/A
- MRBK 18.84
- 52 Week Low
- MCRB $6.53
- MRBK $11.16
- 52 Week High
- MCRB $24.67
- MRBK $17.33
- Technical
- Relative Strength Index (RSI)
- MCRB 51.80
- MRBK 49.60
- Support Level
- MCRB $12.48
- MRBK $14.35
- Resistance Level
- MCRB $14.35
- MRBK $15.10
- Average True Range (ATR)
- MCRB 1.18
- MRBK 0.45
- MACD
- MCRB 0.22
- MRBK 0.03
- Stochastic Oscillator
- MCRB 80.50
- MRBK 61.54
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.